Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 8/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 5/20 | 0.45 |
| ▸ | CA9 | Q16790 | 4/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.42 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.42 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.42 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.42 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL474202 | 1.00 | CA2 (0.53) | CA2TAAR1LMNAL3MBTL1CA12 | |
| SCHEMBL2495122 | 0.87 | CA2 (0.50) | CA2TAAR1LMNAL3MBTL1CA12 | |
| SCHEMBL845362 | 0.85 | CA2 (0.61) | CA2TAAR1LMNAL3MBTL1CA12 | |
| SCHEMBL4256710 | 0.85 | CA2 (0.61) | CA2TAAR1LMNAL3MBTL1CA12 | |
| SCHEMBL845363 | 0.85 | CA2 (0.61) | CA2TAAR1LMNAL3MBTL1CA12 | |
| SCHEMBL13310248 | 0.84 | CA2 (0.46) | CA2TAAR1CA12CA9CA1 | |
| SCHEMBL19036054 | 0.84 | CA2 (0.50) | CA2TAAR1LMNAL3MBTL1CA12 | |
| SCHEMBL13310265 | 0.83 | TAAR1 (0.46) | CA2TAAR1LMNAL3MBTL1MAP1LC3B | |
| SCHEMBL5589496 | 0.81 | CA2 (0.57) | CA2TAAR1LMNAL3MBTL1CA12 | |
| SCHEMBL5589495 | 0.81 | CA2 (0.57) | CA2TAAR1LMNAL3MBTL1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230340197-A1 | SCHIFF BASE INCORPORATED DOUBLE METAL CYANIDE CATALYST FOR THE PRODUCTION OF POLYETHER POLYOLS | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2023-10-26 | — | — | US | claimed |
| WO-2025004059-A1 | SYNTHESIS OF POLYETHER POLYOLS BASED LOW DOSAGE GAS HYDRATE INHIBITORS USING DOUBLE METAL CYANIDE CATALYST | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2025-01-02 | — | — | WO | disclosed |
| US-20230340197-A1 | SCHIFF BASE INCORPORATED DOUBLE METAL CYANIDE CATALYST FOR THE PRODUCTION OF POLYETHER POLYOLS | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2023-10-26 | — | — | US | disclosed |
| US-20230340197-A1 | SCHIFF BASE INCORPORATED DOUBLE METAL CYANIDE CATALYST FOR THE PRODUCTION OF POLYETHER POLYOLS | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2023-10-26 | — | — | US | disclosed |
| US-20230340197-A1 | SCHIFF BASE INCORPORATED DOUBLE METAL CYANIDE CATALYST FOR THE PRODUCTION OF POLYETHER POLYOLS | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2023-10-26 | — | — | US | disclosed |
| US-10556873-B2 | Bimodal ligands with macrocyclic and acyclic binding moieties, complexes and compositions thereof, and methods of using | ILLINOIS INSTITUTE OF TECHNOLOGY (US) | 2020-02-11 | — | — | US | disclosed |
| US-10189803-B2 | Synthesis of therapeutic and diagnostic drugs centered on regioselective and stereoselective ring opening of aziridinium ions | ILLINOIS INSTITUTE OF TECHNOLOGY (US) | 2019-01-29 | — | — | US | disclosed |
| US-20170008863-A1 | SYNTHESIS OF THERAPEUTIC AND DIAGNOSTIC DRUGS CENTERED ON REGIOSELECTIVE AND STEREOSELECTIVE RING OPENING OF AZIRIDINIUM IONS | CHONG, HYUN-SOON, PHD | 2017-01-12 | — | — | US | disclosed |
| EP-2112206-B1 | Polymer Composition | ROHM & HAAS (US) | 2016-06-29 | — | — | EP | disclosed |
| EP-2166043-B1 | Thickener composition and method for thickening aqueous systems | ROHM & HAAS (US) | 2016-04-27 | — | — | EP | disclosed |
| EP-2112206-A1 | Polymer Composition | Rohm and Haas Company (US) | 2009-10-28 | — | — | EP | disclosed |
| US-20080234411-A1 | Thickener composition and method for thickening aqueous systems | ROHM AND HAAS COMPANY | 2008-09-25 | — | — | US | disclosed |
| EP-1972665-A2 | Thickener composition and method for thickening aqueous systems | Rohm and Haas Company (US) | 2008-09-24 | — | — | EP | disclosed |
| US-20080161294-A1 | Urea derivative, medicinal composition containing the same, and medicinal use of these | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2008-07-03 | — | — | US | disclosed |
| EP-1867639-A1 | UREA DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE OF THESE | Kissei Pharmaceutical Co., Ltd. (JP) | 2007-12-19 | — | — | EP | disclosed |
| US-4220589-A | N-(Oxazolidinothio) imides that provide scorch retardant nonblooming elastomeric compositions | PENNWALT CORPORATION (US) | 1980-09-02 | — | — | US | disclosed |
| US-4008244-A | VULCANIZATION ACCELERATORS | PENNWALT CORPORATION (US) | 1977-02-15 | — | — | US | disclosed |
| US-3987017-A | OXAZOLIDINE- OR THIAZOLIDINE-CARBODI-THIOATES AS CURE ACCELERATORS | PENNWALT CORPORATION (US) | 1976-10-19 | — | — | US | disclosed |
| US-3976648-A | VULCANIZATION ACCELERATORS | PENNWALT CORPORATION (US) | 1976-08-24 | — | — | US | disclosed |
| US-3943143-A | Oxazolidine and thiazolidine derived carbodithioate compositions useful as vulcanization accelerators | PENNWALT CORPORATION (US) | 1976-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10556873-B2 | Bimodal ligands with macrocyclic and acyclic binding moieties, complexes and compositions thereof, and methods of using | UACA, CLTC, CLTA | CA2 123/4885TAAR1 548/4885LMNA 658/4885 |
| US-20080161294-A1 | Urea derivative, medicinal composition containing the same, and medicinal use of these | AVPR2, UTS2R, GPR119 | CA2 1652/4885TAAR1 503/4885LMNA 3989/4885 |
| US-20170008863-A1 | SYNTHESIS OF THERAPEUTIC AND DIAGNOSTIC DRUGS CENTERED ON REGIOSELECTIVE AND STEREOSELECTIVE RING OPENING OF AZIRIDINIUM IONS | AZI2, ABL1, DHPS | CA2 48/4885TAAR1 2219/4885LMNA 4686/4885 |
| US-10189803-B2 | Synthesis of therapeutic and diagnostic drugs centered on regioselective and stereoselective ring opening of aziridinium ions | AZI2, ABL1, DHPS | CA2 48/4885TAAR1 2219/4885LMNA 4686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.